Results 131 to 140 of about 3,604,017 (310)

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang   +6 more
wiley   +1 more source

Learning in Evolutionary Environments [PDF]

open access: yes
The purpose of this work is to present a sort of short selective guide to an enormous and diverse literature on learning processes in economics. We argue that learning is an ubiquitous characteristic of most economic and social systems but it acquires ...
Luigi Marengo   +2 more
core  

Trayectorias evolucionistas en la dinámica de la empresa: una aproximación por dinámica de sistemas

open access: yesIngeniería e Investigación, 2006
La actividad de las firmas, como unidad socioeconómica, en el marco evolucionista está orientada integralmente por procesos de identidad, cohesión y mecanismos de adaptación y evolución; en este orden, el presente documento ilustra, a través de un modelo
Germán Eduardo Vargas
doaj  

Economic evaluations of antiobesity medications: A systematic literature review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The global prevalence of obesity is rising rapidly. With several antiobesity medications approved and many more in development, understanding their economic value is increasingly important. This study reviews full economic evaluations of approved antiobesity medications to assess cost‐effectiveness and inform reimbursement and access decisions.
Martina Jurković   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy